Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis

NCT ID: NCT03664596

Last Updated: 2021-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-01
• Study Completion Date: 2020-12-01

Brief Summary

This study evaluates the dietary and therapeutic effect of supplement consisting of sublimated mare milk among patients with non-alcoholic steatohepatitis.

Detailed Description

Nonalcoholic steatohepatitis (NASH) is characterized by the liver damage in the form of fatty degeneration and hepatitis in people who do not abuse alcohol. The disease often develops in middle-aged women with excessive body weight, increased blood glucose and blood lipids, but can occur in all age groups and in both sexes. In most cases, the disease is asymptomatic. Laboratory data indicate an increase in the level of aminotransaminases. Ultrasound reveals hyperechoic tissue of the liver due to diffuse fatty infiltration. The degree of steatosis can also be estimated by a controlled attenuation parameter (CAP - Controlled Attenuation Parameter) in the fibroelastometry of liver tissue. It is also possible to verify the degree of fibrosis of liver tissue in its presence. Given that the mare's milk has therapeutic and dietary properties for various diseases of the internal organs, including liver diseases, the investigators decided to study its therapeutic effectiveness in NASH.

In this clinical study, the effectiveness of mare's milk in NASH will be studied in comparison with control groups taking monotherapy with ursodeoxycholic acid (UDCA) and combined therapy (mare's milk and UDCA). Patients will receive a sublimated form of mare's milk in the appropriate dosage within 2 months, and the results of clinical laboratory and instrumental studies will be compared among themselves using statistical methods.

Conditions

Non-alcoholic Steatohepatitis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dietary supplement only

Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.

Group Type: EXPERIMENTAL

Sublimated mare's milk

Intervention Type: DIETARY_SUPPLEMENT

Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).

Dietary supplement and ursodeoxycholic acid therapy

Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.

Group Type: OTHER

Sublimated mare's milk

Intervention Type: DIETARY_SUPPLEMENT

Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).

Ursodeoxycholic Acid

Intervention Type: DRUG

Ursodeoxycholic acid in the form of 250 mg capsule.

Ursodeoxycholic acid therapy only

Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.

Group Type: ACTIVE_COMPARATOR

Ursodeoxycholic Acid

Intervention Type: DRUG

Ursodeoxycholic acid in the form of 250 mg capsule.

Interventions

Sublimated mare's milk

Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).

Intervention Type: DIETARY_SUPPLEMENT

Ursodeoxycholic Acid

Ursodeoxycholic acid in the form of 250 mg capsule.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with a verified diagnosis of non-alcoholic steatohepatitis;
• Aged 16 to 60 years;
• Absence of an allergic reaction to dairy products;
• Willingness to consent to participate in the study.
• Consent to adhere to treatment

Exclusion Criteria

• Taking antibiotics, cytostatics and steroids during the last 3 months;
• Taking alcohol hepatotoxic doses (no more than 30 g alcohol per day for men and not more than 20 g for women);
• History of oncological diseases;
• Presence of diabetes mellitus, decompensated forms of diseases, intestinal dyspepsia, hypertension (blood pressure 140/90 mm Hg and more at the time of the initial visit to the doctor), tuberculosis;
• A positive result of screening for antibodies to viral hepatitis B, C and D, as well as HIV
• Presence of concomitant diseases of the kidneys, liver, cardiovascular, respiratory and other body systems, oncological, mental health and decompensated endocrine diseases, tuberculosis, and HIV infection;
• Pregnancy and/or lactation;
• Patient involvement in other clinical trials within the last 3 months;
• Refusal to participate in the study.

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eurasia Invest Ltd.

INDUSTRY

Sponsor Role: collaborator

Ministry of Education and Science, Republic of Kazakhstan

OTHER_GOV

Sponsor Role: collaborator

Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Medical Centre Hospital of the President's Affairs Administration

Astana, , Kazakhstan

Countries

Kazakhstan

References

Sidhu GS, Brown MA, Johnson AR. Autoxidation in milk rich in linoleic acid. I. An objective method of measuring autoxidation and evaluating antioxidants. J Dairy Res. 1975 Feb;42(1):185-95. doi: 10.1017/s0022029900015211.

Reference Type: BACKGROUND

PMID: 1123470 (View on PubMed)

Sidhu GS, Brown MA, Johnson AR. Autoxidation in milk rich in linoleic acid. II. Modification of the initiation system and control of oxidation. J Dairy Res. 1976 Jun;43(2):239-50. doi: 10.1017/s002202990001579x.

Reference Type: BACKGROUND

PMID: 956472 (View on PubMed)

Rong J, Zheng H, Liu M, Hu X, Wang T, Zhang X, Jin F, Wang L. Probiotic and anti-inflammatory attributes of an isolate Lactobacillus helveticus NS8 from Mongolian fermented koumiss. BMC Microbiol. 2015 Oct 2;15:196. doi: 10.1186/s12866-015-0525-2.

Reference Type: BACKGROUND

PMID: 26428623 (View on PubMed)

Aryantini NP, Yamasaki E, Kurazono H, Sujaya IN, Urashima T, Fukuda K. In vitro safety assessments and antimicrobial activities of Lactobacillus rhamnosus strains isolated from a fermented mare's milk. Anim Sci J. 2017 Mar;88(3):517-525. doi: 10.1111/asj.12668. Epub 2016 Aug 1.

Reference Type: BACKGROUND

PMID: 27476815 (View on PubMed)

Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013 Oct 28;19(40):6911-8. doi: 10.3748/wjg.v19.i40.6911.

Reference Type: BACKGROUND

PMID: 24187469 (View on PubMed)

Zhang B, Lu XL, Song YH, Shi HT, Li J, Geng Y. [Changes in the intestinal microenvironment during development of alcoholic fatty liver disease and related effects of probiotic therapy]. Zhonghua Gan Zang Bing Za Zhi. 2012 Nov;20(11):848-52. doi: 10.3760/cma.j.issn.1007-3418.2012.11.010. Chinese.

Reference Type: BACKGROUND

PMID: 23206305 (View on PubMed)

Valiev AG, Valieva TA, Valeeva GR, Speranskii VV, Levachev MM. [The effect of the essential fatty acids in mare's milk on the function of the immune system and of nonspecific resistance in rats]. Vopr Pitan. 1999;68(3):3-6. Russian.

Reference Type: BACKGROUND

PMID: 10392421 (View on PubMed)

Abdel-Salam AM, Al-Dekheil A, Babkr A, Farahna M, Mousa HM. High fiber probiotic fermented mare's milk reduces the toxic effects of mercury in rats. N Am J Med Sci. 2010 Dec;2(12):569-75. doi: 10.4297/najms.2010.2569.

Reference Type: BACKGROUND

PMID: 22558569 (View on PubMed)

Guri A, Paligot M, Crevecoeur S, Piedboeuf B, Claes J, Daube G, Corredig M, Griffiths MW, Delcenserie V. In vitro screening of mare's milk antimicrobial effect and antiproliverative activity. FEMS Microbiol Lett. 2016 Jan;363(2):fnv234. doi: 10.1093/femsle/fnv234. Epub 2015 Dec 9.

Reference Type: BACKGROUND

PMID: 26656278 (View on PubMed)

Oshakbayev K, Bimbetov B, Manekenova K, Bedelbayeva G, Mustafin K, Dukenbayeva B. Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. Curr Med Res Opin. 2019 Jan;35(1):157-165. doi: 10.1080/03007995.2018.1547696. Epub 2018 Nov 28.

Reference Type: RESULT

PMID: 30431378 (View on PubMed)

Bimbetov B., Zhangabylov A., Aitbaeva S., Rakhimzhanova M, Bakytzhanuly A. The result of taking mare's milk for nonalcoholic steatohepatitis // Journal of Global Pharma Technology. Volume 11 Issue 08 (2019) August 2019. -Р.268-273.

Reference Type: RESULT

Bimbetov B., Zhangabylov A., Aitbaeva S., Bakytzhanuly A., Utepbergenova G. Use of the mare's milk of the treatment of non-alcoholic steatohepatitis // Systematic Reviews in Pharmacy. -2020.

Reference Type: RESULT

Other Identifiers

UDP.NAS.01

Identifier Type: -

Identifier Source: org_study_id